The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia Indications for and implications of germline ...
New Molecular Targets in Prostate Cancer—The Emerging Role of ACP1 and Low Molecular Weight Protein Tyrosine Phosphatase Fig 1. (A) Mechanism of nectin-4–mediated cancer progression. (B) Mechanism of ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...
Patients were stratified to cohort A (unspecified tumors) or cohort B (rare genomic alterations). The TARGET-CRM design permits cohort B patients to immediately enroll at one dose level below the ...
Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease Seventy patients were enrolled, 33 (47%) had a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback